In hospitalized medical patients, what pharmacologic DVT prophylaxis is used and what considerations apply?

Study for the Medical Council of Canada Qualifying Examination (MCCQE) I. Engage with flashcards and multiple-choice questions with detailed feedback. Prepare confidently!

Multiple Choice

In hospitalized medical patients, what pharmacologic DVT prophylaxis is used and what considerations apply?

In hospitalized medical patients, preventing DVT relies on parenteral anticoagulation given as prophylaxis. The options of choice are low-molecular-weight heparin or unfractionated heparin, administered at prophylactic doses. The crucial consideration is renal function: LMWH is cleared by the kidneys, so in patients with reduced renal function the dose must be adjusted or a switch to unfractionated heparin is made, because UFH can be dosed and reversed more readily in renal impairment. Both agents carry bleeding risk and a small risk of heparin-induced thrombocytopenia, with HIT being more common with unfractionated heparin but still a consideration with LMWH. Direct oral anticoagulants are not universally used as first-line inpatient prophylaxis in medical patients due to bleeding risk and limited, sometimes conflicting evidence in this setting. Warfarin monotherapy is not suitable for inpatient prophylaxis because it takes days to achieve anticoagulation and requires monitoring and dose adjustment. Aspirin alone provides less protection against VTE and is generally not adequate as sole pharmacologic prophylaxis for high-risk medical inpatients. So, the best approach is parenteral prophylaxis with LMWH or UFH, tailored to the patient’s renal function.

In hospitalized medical patients, preventing DVT relies on parenteral anticoagulation given as prophylaxis. The options of choice are low-molecular-weight heparin or unfractionated heparin, administered at prophylactic doses. The crucial consideration is renal function: LMWH is cleared by the kidneys, so in patients with reduced renal function the dose must be adjusted or a switch to unfractionated heparin is made, because UFH can be dosed and reversed more readily in renal impairment. Both agents carry bleeding risk and a small risk of heparin-induced thrombocytopenia, with HIT being more common with unfractionated heparin but still a consideration with LMWH.

Direct oral anticoagulants are not universally used as first-line inpatient prophylaxis in medical patients due to bleeding risk and limited, sometimes conflicting evidence in this setting. Warfarin monotherapy is not suitable for inpatient prophylaxis because it takes days to achieve anticoagulation and requires monitoring and dose adjustment. Aspirin alone provides less protection against VTE and is generally not adequate as sole pharmacologic prophylaxis for high-risk medical inpatients.

So, the best approach is parenteral prophylaxis with LMWH or UFH, tailored to the patient’s renal function.

More practice questions